MUNICH and CALGARY, Aug. 28, 2012 /PRNewswire/ - Resverlogix Corp. (TSX: RVX) today announced that the BET protein inhibitor RVX-208 significantly increased HDL-C (p=0.001), the primary endpoint of ...

Resverlogix Corp. has announced findings from the recent analysis of Major Adverse Cardiovascular Events (MACE) data in patients with diabetes mellitus (DM) enrolled in both the ASSURE and SUSTAIN ...

We are initiating coverage of Resverlogix Corp. (RVX.TO) (RVXCF) with a "Hold" rating and a $3.25 price target. Resverlogix Corp. is a clinical stage cardiovascular company with an epigenetic platform ...

January 20, 2011 (Cleveland, Ohio) — Larger long-term studies may be able to show that that RVX-208, the first oral agent for raising high-density-lipoprotein cholesterol (HDL-C) through ...

In this article, I’m going to take a look at Resverlogix Corp’s (TSX:RVX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors.

AMSTERDAM, The Netherlands—A new oral agent known as RVX-208 has failed to induce more than a trend toward plaque regression compared with placebo at 6-month follow-up. Findings from the ASSURE study ...

Our first exposure to the Klipsch RVX-54 Home Theater Speaker System came while touring the sea of electronics on the convention floor at the 2005 Consumer Electronics Show (CES) in Las Vegas. In a ...

Provider of software and technology for the reverse mortgage industry, ReverseVision announced yesterday that it has completed an integration with the program, ServiceLink Flood, from the national ...

The new RVX show may have been formed with the goal of attracting new, adventurous buyers (the crossover utility vehicle set, if you will), but it was still a sea of huge, lumbering mobile homes that ...

A new partnership announced between ReverseVision and Factual Data gives reverse mortgage loan originators the opportunity to use integrated credit reporting solutions on ReverseVision’s RV Exchange ...